Connor, Clark & Lunn Investment Management (CC&L)’s Nurix Therapeutics NRIX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-44,976	Closed	-$697K	–	1741
2026 Q1	$697K	Buy	+44,976	New	+$746K	﹤0.01%	1242
2025 Q4	–	Sell	-61,515	Closed	-$568K	–	1702
2025 Q3	$568K	Buy	+61,515	New	+$639K	﹤0.01%	1222
2024 Q3	–	Sell	-62,298	Closed	-$1.3M	–	1582
2024 Q2	$1.3M	Sell	62,298 -174,806	-74%	-$2.72M	0.01%	783
2024 Q1	$3.49M	Buy	237,104 +52,034	+28%	+$560K	0.02%	513
2023 Q4	$1.91M	Buy	185,070 +1,147	+0.6%	+$7.86K	0.01%	679
2023 Q3	$1.45M	Buy	183,923 +53,429	+41%	+$488K	0.01%	705
2023 Q2	$1.3M	Buy	130,494 +117,446	+900%	+$1.2M	0.01%	716
2023 Q1	$116K	Buy	+13,048	New	+$136K	﹤0.01%	1140

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Connor, Clark & Lunn Investment Management (CC&L)'s NRIX Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 44,976 shares — an estimated $697K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NRIX in Q1 2023 and held it in 8 quarters. The position peaked at $3.49M in Q1 2024. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 44,976 Nurix Therapeutics shares in Q2 2026, an estimated $697K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Nurix Therapeutics in Q1 2023 and held it in 8 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Nurix Therapeutics position peaked at $3.49M in Q1 2024.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.